| Year |
Citation |
Score |
| 2020 |
Gilmore W, Lund BT, Li P, Levy AM, Kelland EE, Akbari O, Groshen S, Cen SY, Pelletier D, Weiner LP, Javed A, Dunn JE, Traboulsee AL. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis. Journal of Neuroinflammation. 17: 189. PMID 32539719 DOI: 10.1186/S12974-020-01847-9 |
0.3 |
|
| 2018 |
Koskimäki F, Bernard J, Yong J, Arndt N, Carroll T, Lee SK, Reder AT, Javed A. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. Plos One. 13: e0209326. PMID 30576361 DOI: 10.1371/Journal.Pone.0209326 |
0.316 |
|
| 2017 |
Talmage GD, Coppes OJM, Javed A, Bernard J. Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study. Plos One. 12: e0173299. PMID 28426702 DOI: 10.1371/Journal.Pone.0173299 |
0.332 |
|
| 2012 |
Javed A, Williamson E, Shi L. White and Gray Matter Changes in Early Multiple Sclerosis (P03.049) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P03.049 |
0.313 |
|
| 2008 |
Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, Weiner H, Weinstock-Guttman B, Khan O. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. The Lancet. Neurology. 7: 173-83. PMID 18207115 DOI: 10.1016/S1474-4422(08)70020-6 |
0.31 |
|
| 2006 |
Javed A, Reder AT. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacology & Therapeutics. 110: 35-56. PMID 16229894 DOI: 10.1016/J.Pharmthera.2005.08.011 |
0.302 |
|
| 2001 |
Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS. 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 3572-9. PMID 11331386 DOI: 10.1523/Jneurosci.21-10-03572.2001 |
0.589 |
|
| 1999 |
Javed A, Kamradt MC, Van de Kar LD, Gray TS. D-Fenfluramine induces serotonin-mediated Fos expression in corticotropin-releasing factor and oxytocin neurons of the hypothalamus, and serotonin-independent Fos expression in enkephalin and neurotensin neurons of the amygdala. Neuroscience. 90: 851-8. PMID 10218785 DOI: 10.1016/S0306-4522(98)00523-5 |
0.599 |
|
| 1999 |
Singh S, Johnson PI, Javed A, Gray TS, Lonchyna VA, Wurster RD. Monoamine- and histamine-synthesizing enzymes and neurotransmitters within neurons of adult human cardiac ganglia. Circulation. 99: 411-9. PMID 9918529 DOI: 10.1161/01.Cir.99.3.411 |
0.508 |
|
| 1998 |
Javed A, Van de Kar LD, Gray TS. The 5-HT1A and 5-HT2A/2C receptor antagonists WAY-100635 and ritanserin do not attenuate D-fenfluramine-induced fos expression in the brain. Brain Research. 791: 67-74. PMID 9593827 DOI: 10.1016/S0006-8993(98)00082-1 |
0.593 |
|
| 1997 |
Javed A, Van De Kar LD, Gray TS. p-Chlorophenylalanine and fluoxetine inhibit D-fenfluramine-induced Fos expression in the paraventricular nucleus, cingulate cortex and frontal cortex but not in other forebrain and brainstem regions. Brain Research. 774: 94-105. PMID 9452197 DOI: 10.1016/S0006-8993(97)81692-7 |
0.593 |
|
| Show low-probability matches. |